Commentary
In patients with moderate-to-severe plaque psoriasis, biologic therapy has become a mainstay of treatment. Of recent agents, tildrakizumab is a monoclonal antibody targeting interleukin-23 (IL-23) that has been approved for treatment of moderate-to-severe plaque psoriasis in several countries worldwide [1]. While phase III clinical trials and subsequent open-label extension studies have evaluated its efficacy and safety, real-world evidence involving patients from routine clinical practice is limited [1, 2].
While our group previously reported real-world drug survival outcomes of up to 3 years with tildrakizumab, this subset analysis focuses on its effectiveness and safety [1].
We included adult patients with plaque psoriasis that received tildrakizumab from 14 centers in Canada, Spain, Italy, Portugal, and Switzerland. Patients were initiated on tildrakizumab as per standard dosing. The study design has been previously described [1].
The primary effectiveness outcome measured was absolute Psoriasis Area and Severity Index (PASI) score. A modified Non-Responder Imputation (mNRI) analysis was applied for response-related discontinuation. Safety was measured via adverse events (AEs).
The study was conducted using anonymized and deidentified data in adherence with ethical standards with institutional research board (IRB) approval at the academic institutions involved.
This analysis identified 517 patients. The mean age was 50.1 (SD ± 15.8) years with 61.5% (318/517) being male (Table 1); 74.1% (383/517) and 35% (181/517) patients had previously utilized conventional systemic therapy/phototherapy or biologics, respectively. We identified 426, 315, and 148 patients who continued tildrakizumab at year 1, 2, and 3, respectively.
Table 1Baseline demographic and clinical characteristics for adult patients with moderate-to-severe plaque psoriasis treated with tildrakizumabDemographic and clinical characteristicsValueSex, n (%) Male318 (61.5) Female199 (38.5) Baseline age (years), mean ± SD50.1 ± 15.8 Disease duration (years), mean ± SD16.8 ± 12.5 Baseline BMI, mean ± SD26.3 ± 4.3Comorbidities, n (%) Hypertension137 (26.5) Dyslipidemia126 (24.4) Obesity70 (13.5) PsA42 (8.1) Latent tuberculosis50 (9.7) Hepatitis B13 (2.5) Hepatitis C12 (2.3) Inflammatory bowel disease4 (0.8)Smoking status, n (%) Smoker133 (25.7)Previous treatments, n (%) Phototherapy146 (28.2) Systemic non-biologic therapy383 (74.1) Methotrexate†201 (39.1) Cyclosporine†150 (29) Retinoids†96 (18.6) Apremilast†11 (2.1) Systemic biologic therapy181 (35) Adalimumab‡113 (21.9) Secukinumab‡37 (7.2) Ustekinumab‡37 (7.2) Etanercept‡36 (6.7) Ixekizumab‡24 (4.6) Risankizumab‡16 (3.1) Guselkumab‡11 (2.1) Infliximab§10 (1.9) Brodalumab‡8 (1.6) Certolizumab‡2 (0.4) Bimekizumab‡1 (0.2)Number of prior biologic treatments 1117 (22.6) 240 (7.7) ≥ 324 (4.6) Baseline PASI, mean ± SD11.5 ± 6BMI body mass index; n number of patients meeting criteria; PASI psoriasis area and severity index; PsA psoriatic arthritis; SD standard deviation†Oral route ‡subcutaneous route §intravenous route
At 1 year (n = 426), 87.6% (373/426), 69.3% (295/426), and 50% (213/426) achieved absolute PASI scores ≤ 3, ≤ 1, and 0, respectively. At 2 years (n = 315), 80.3% (253/315), 63.2% (199/315), and 51.1% (161/315) achieved absolute PASI scores ≤ 3, ≤ 1, and 0, respectively. Finally, at 3 years (n = 148), 78.4% (116/148), 61.5% (91/148), and 48% (71/148) reached absolute PASI scores ≤ 3, ≤ 1, and 0, respectively (Table 2).
Achievement of PASI ≤ 3 (at years 1 and 3) was found to be significantly higher in biologic-naïve versus biologic-experienced patients (Supplementary Table 1, Supplementary Table 2). Response rates were not impacted by obesity (BMI ≥ 30) status (Supplementary Table 2). During treatment, 3.1% (16/517) underwent dose escalation of tildrakizumab (from 100 to 200 mg), and 1.4% (7/517) used concomitant systemic therapies.
Table 2Effectiveness and safety outcomes for tildrakizumab treatment in adult patients with moderate-to-severe plaque psoriasisEffectiveness and safety outcomesValueEffectiveness outcomes at 1 yearn/N (%) PASI ≤ 3373/426 (87.6) PASI ≤ 1295/426 (69.3) PASI 0213/426 (50)Effectiveness outcomes at 2 years PASI ≤ 3253/315 (80.3) PASI ≤ 1199/315 (63.2) PASI 0161/315 (51.1)Effectiveness outcomes at 3 years PASI ≤ 3116/148 (78.4) PASI ≤ 191/148 (61.5) PASI 071/148 (48)Mean ± SD PASI after 1 year of treatment1.1 ± 2 PASI after 2 years of treatment1.2 ± 0.5 PASI after 3 years of treatment1.3 ± 2.1 Safety outcomesn/N (%)Treatment-emergent adverse events of special interest Infection29/517 (5.6) Infection leading to hospitalization1/517 (0.2) Injection site reaction3/517 (0.6) Malignancy2/517 (0.4)Carcinoid tumor1/517 (0.2)Follicular lymphoma1/517 (0.2) Heart failure1/517 (0.2) Hepatic abnormalities0/517 (0)n number of patients meeting criteria; PASI psoriasis area and severity index; PASI75 75% improvement in psoriasis area and severity index from baseline; SD standard deviation
In this cohort of patients, 10.8% (56/517) experienced treatment-emergent AEs (TEAEs) (Table 2, Supplementary Table 3). Of these, infection was most common (5.6%, 29/517), with 0.2% (1/517) of patients requiring hospitalization. Malignancy was documented in 0.4% (2/517) of patients.
Injection site reaction was documented in 0.6% (3/517). Regarding cardiac AEs, one patient (0.2%) received a new diagnosis of heart failure (New York Heart Association Functional Class III) during tildrakizumab treatment. No hepatic abnormalities were observed.
Eighty-eight (17%) patients discontinued tildrakizumab with reasons including lack of efficacy (9.5%, 49/517) and AEs (2.3%, 12/517: infection [n = 6]; malignancy [n = 2]; lymphocytosis [n = 1], myalgia [n = 1]; uncontrolled dyslipidemia [n = 1]; alopecia areata [n = 1]). Safety data were further explored in our previously reported drug survival analysis [1].
Our real-world absolute PASI outcomes for tildrakizumab at years 1 and 3 are comparable to NRI outcomes from open-label extension studies (reSURFACE 1 and reSURFACE 2) at weeks 52 and weeks 148 [2]. A similar study from Italy (n = 136) is the longest real-world follow-up of tildrakizumab to date, which demonstrated 84.4% achievement of PASI ≤ 2 [3]. For 3 years, our safety data were consistent with open-label extension studies at the same timepoint, including for TEAEs of special interest [4, 5].
Of note, in our previous analysis of this cohort, we identified a real-world drug survival of 91.3% at 1 year, 85.3% at 2 years, and 82.4% at 3 years for patients, revealing that tildrakizumab is favorably tolerated in the long term and further supporting our effectiveness/safety results [1]. Study limitations include its small sample size, retrospective nature, a lack of available laboratory monitoring data, and a lack of available effectiveness metrics aside from PASI. Overall, our real-world data support the long-term use of tildrakizumab for plaque psoriasis.
Supplementary Information
Below is the link to the electronic supplementary material.Supplementary file1 (PDF 162 KB)